Phosphorylated Tau Levels in Donated Blood
ConditionAlzheimer&Amp;#39;s Disease
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorThe University of Texas Health Science Center, Houston
About this trial
Alzheimer's disease (AD) is characterized by the accumulation of tau pathology, and blood-based biomarkers such as phosphorylated tau-217 (pTau217) have been identified as sensitive and specific predictors of AD risk. Recent studies suggest that individuals with elevated pTau217 levels may be at increased risk for developing AD and cognitive dysfunction. This observational study will examine donated human plasma samples to determine whether some units of donated blood contain abnormally elevated pTau217 concentrations. The overarching goal is to evaluate whether transfusion of blood with higher pTau217 may pose risks to recipients and whether such units should be avoided in clinical use.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
The plasma sample from donators.
Disqualifiers
None.
Trial population
Anybody who can donate blood.
Trial design
Design model
Other
Time perspective
Other
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Tau and pTau
Concentration of Tau and pTau217 in plasma.
Time frame
6 months.2
Concentration of pTau217 and Tau
We will use nanoneedle technology to measure the concentration of Tau and pTau217 in collected plasma samples from blood donators.
Time frame
6 months.Sponsors and contacts
Click on the lead sponsor to view all of their trials.
The University of Texas Health Science Center, Houston
Lead sponsor
National Institute on Aging (NIA)
Collaborator
Source ClinicalTrials.gov